AR061815A1 - Compuesto de oxo-prolinamida composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento - Google Patents
Compuesto de oxo-prolinamida composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamentoInfo
- Publication number
- AR061815A1 AR061815A1 ARP070102985A ARP070102985A AR061815A1 AR 061815 A1 AR061815 A1 AR 061815A1 AR P070102985 A ARP070102985 A AR P070102985A AR P070102985 A ARP070102985 A AR P070102985A AR 061815 A1 AR061815 A1 AR 061815A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkynyl
- alkenyl
- alkyl
- optionally substituted
- halogen
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- HWHWCOBKVKZESC-BYPYZUCNSA-N (2s)-3-oxopyrrolidine-2-carboxamide Chemical compound NC(=O)[C@H]1NCCC1=O HWHWCOBKVKZESC-BYPYZUCNSA-N 0.000 title 1
- 239000002131 composite material Substances 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 5
- 125000005843 halogen group Chemical group 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 3
- 150000002431 hydrogen Chemical class 0.000 abstract 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 102100037602 P2X purinoceptor 7 Human genes 0.000 abstract 2
- 101710189965 P2X purinoceptor 7 Proteins 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000005002 aryl methyl group Chemical group 0.000 abstract 2
- 125000004981 cycloalkylmethyl group Chemical group 0.000 abstract 2
- 229910052731 fluorine Inorganic materials 0.000 abstract 2
- 239000011737 fluorine Substances 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- -1 Oxo-prolinamide compound Chemical class 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 230000036407 pain Effects 0.000 abstract 1
- 125000006513 pyridinyl methyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0613473A GB0613473D0 (en) | 2006-07-06 | 2006-07-06 | Novel compounds |
| GB0622825A GB0622825D0 (en) | 2006-11-15 | 2006-11-15 | Novel compounds |
| GB0705263A GB0705263D0 (en) | 2007-03-19 | 2007-03-19 | Novel compounds |
| GB0711439A GB0711439D0 (en) | 2007-06-13 | 2007-06-13 | Novel receptor antagonists and their methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR061815A1 true AR061815A1 (es) | 2008-09-24 |
Family
ID=38508907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070102985A AR061815A1 (es) | 2006-07-06 | 2007-07-04 | Compuesto de oxo-prolinamida composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US7718693B2 (enExample) |
| EP (1) | EP2049478B1 (enExample) |
| JP (1) | JP5283620B2 (enExample) |
| KR (2) | KR101398264B1 (enExample) |
| AR (1) | AR061815A1 (enExample) |
| AU (1) | AU2007271182B2 (enExample) |
| BR (1) | BRPI0714062A2 (enExample) |
| CA (1) | CA2655675A1 (enExample) |
| CR (2) | CR10545A (enExample) |
| CY (1) | CY1113415T1 (enExample) |
| DK (1) | DK2049478T3 (enExample) |
| EA (1) | EA016076B1 (enExample) |
| ES (1) | ES2385505T3 (enExample) |
| HR (1) | HRP20120505T1 (enExample) |
| IL (1) | IL196181A0 (enExample) |
| MA (1) | MA30607B1 (enExample) |
| MX (1) | MX2009000117A (enExample) |
| NO (1) | NO20090267L (enExample) |
| PE (1) | PE20080997A1 (enExample) |
| PL (1) | PL2049478T3 (enExample) |
| PT (1) | PT2049478E (enExample) |
| SI (1) | SI2049478T1 (enExample) |
| TW (1) | TW200819127A (enExample) |
| UA (1) | UA100227C2 (enExample) |
| WO (1) | WO2008003697A1 (enExample) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2372955T3 (es) | 2006-07-06 | 2012-01-30 | Array Biopharma, Inc. | Ciclopenta[d]pirimidinas como inhibidores de la proteína cinasa akt. |
| US8063050B2 (en) | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| JP5231411B2 (ja) | 2006-07-06 | 2013-07-10 | アレイ バイオファーマ、インコーポレイテッド | Ａｋｔプロテインキナーゼ阻害剤としてのジヒドロチエノピリミジン |
| ATE493418T1 (de) | 2006-07-06 | 2011-01-15 | Array Biopharma Inc | Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren |
| PL2049478T3 (pl) | 2006-07-06 | 2012-09-28 | Glaxo Group Ltd | Podstawione N-fenylometylo 5-okso-prolino-2-amidy jako antagoniści receptora P2X7 oraz sposoby ich zastosowania |
| DE102006047619B4 (de) * | 2006-10-09 | 2008-11-13 | Clariant International Limited | Verfahren zur Herstellung basischer Fettsäureamide |
| DE102006047617B4 (de) * | 2006-10-09 | 2008-11-27 | Clariant International Limited | Verfahren zur Herstellung basischer (Meth)acrylamide |
| CA2934202A1 (en) * | 2006-10-22 | 2008-05-02 | Idev Technologies, Inc. | Methods for securing strand ends and the resulting devices |
| GB0705882D0 (en) * | 2007-03-27 | 2007-05-02 | Glaxo Group Ltd | Novel compounds |
| JP2010522711A (ja) * | 2007-03-28 | 2010-07-08 | グラクソ グループ リミテッド | Ｐ２ｘ７調節因子としてのピペリジノンカルボキサミド誘導体 |
| JP2010522710A (ja) * | 2007-03-29 | 2010-07-08 | グラクソ グループ リミテッド | Ｐ２ｘ７調節因子としてのオキサゾリジンおよびモルホリンカルボキサミド誘導体 |
| WO2008119825A2 (en) * | 2007-04-03 | 2008-10-09 | Glaxo Group Limited | Imidazolidine carboxamide derivatives as p2x7 modulators |
| US9409886B2 (en) | 2007-07-05 | 2016-08-09 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| NZ582692A (en) | 2007-07-05 | 2012-05-25 | Array Biopharma Inc | Pyrimidyl cyclopentanes as akt protein kinase inhibitors |
| US8846683B2 (en) | 2007-07-05 | 2014-09-30 | Array Biopharma, Inc. | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors |
| US8377937B2 (en) | 2007-07-05 | 2013-02-19 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| WO2009074518A1 (en) * | 2007-12-12 | 2009-06-18 | Glaxo Group Limited | Combinations of prolinamide p2x7 modulators with further therapeutic agents |
| EP2231153A2 (en) * | 2007-12-18 | 2010-09-29 | Glaxo Group Limited | 5-oxo-3-pyrrolidinecarboxamide derivatives as p2x7 modulators |
| GB0724625D0 (en) * | 2007-12-18 | 2008-01-30 | Glaxo Group Ltd | Novel compounds |
| WO2009089459A1 (en) | 2008-01-09 | 2009-07-16 | Array Biopharma Inc. | Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors |
| CA2711692A1 (en) | 2008-01-09 | 2009-07-16 | Array Biopharma Inc. | Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor |
| GB0803729D0 (en) * | 2008-02-29 | 2008-04-09 | Ge Healthcare Ltd | Imaging the central nervous system |
| ES2357682T3 (es) | 2008-03-25 | 2011-04-28 | Affectis Pharmaceuticals Ag | Antagonistas de p2x7r novedosos y su utilización. |
| DE102008017217A1 (de) * | 2008-04-04 | 2009-10-08 | Clariant International Ltd. | Kontinuierliches Verfahren zur Herstellung von Amiden aromatischer Carbonsäuren |
| DE102008017216B4 (de) * | 2008-04-04 | 2013-08-14 | Clariant International Ltd. | Kontinuierliches Verfahren zur Herstellung von Fettsäureamiden |
| DE102008017214B4 (de) * | 2008-04-04 | 2012-02-16 | Clariant International Limited | Kontinuierliches Verfahren zur Herstellung von Fettsäurealkanolamiden |
| DE102008017218B4 (de) * | 2008-04-04 | 2011-09-22 | Clariant International Ltd. | Kontinuierliches Verfahren zur Herstellung von Amiden niederer aliphatischer Carbonsäuren |
| DE102008017215B4 (de) * | 2008-04-04 | 2012-08-09 | Clariant International Ltd. | Kontinuierliches Verfahren zur Herstellung von Amiden ethylenisch ungesättigter Carbonsäuren |
| DE102008017219A1 (de) * | 2008-04-04 | 2009-10-08 | Clariant International Ltd. | Verfahren zur Herstellung von Amiden in Gegenwart von überhitztem Wasser |
| DE102008017213B4 (de) * | 2008-04-04 | 2012-08-09 | Clariant International Limited | Kontinuierliches Verfahren zur Herstellung von Amiden aliphatischer Hydroxycarbonsäuren |
| WO2010077836A2 (en) * | 2009-01-05 | 2010-07-08 | Boehringer Ingelheim International Gmbh | Pyrrolidine compounds which modulate the cb2 receptor |
| DK2243772T3 (da) | 2009-04-14 | 2012-02-13 | Affectis Pharmaceuticals Ag | Hidtil ukendte P2X7R-antagonister og deres anvendelse |
| DE102009031059A1 (de) | 2009-06-30 | 2011-01-05 | Clariant International Ltd. | Vorrichtung zur kontinuierlichen Durchführung chemischer Reaktionen bei hohen Temperaturen |
| DE102009042522A1 (de) | 2009-09-22 | 2011-04-07 | Clariant International Ltd. | Kontinuierliches Umesterungsverfahren |
| DE102009042523B4 (de) | 2009-09-22 | 2012-02-16 | Clariant International Ltd. | Vorrichtung und Verfahren zur kontinuierlichen Durchführung heterogen katalysierter chemischer Reaktionen bei hohen Temperaturen |
| ES2710522T3 (es) | 2009-12-08 | 2019-04-25 | Univ Vanderbilt | Procedimientos y composiciones para la extracción de venas y autotransplante |
| CA2792258A1 (en) | 2010-03-05 | 2011-09-09 | President And Fellows Of Harvard College | Induced dendritic cell compositions and uses thereof |
| CN102858741A (zh) | 2010-05-14 | 2013-01-02 | 阿费克蒂斯制药股份公司 | 制备p2x7r拮抗剂的新方法 |
| DE102010056565A1 (de) | 2010-12-30 | 2012-07-05 | Clariant International Ltd. | Verfahren zur Modifizierung Hydroxylgruppen tragender Polymere |
| DE102010056564A1 (de) | 2010-12-30 | 2012-07-05 | Clariant International Limited | Hydroxylgruppen und Estergruppen tragende Polymere und Verfahren zu ihrer Herstellung |
| WO2012093101A1 (en) * | 2011-01-04 | 2012-07-12 | Novartis Ag | Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd) |
| WO2012110190A1 (en) | 2011-02-17 | 2012-08-23 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| US20140187533A1 (en) * | 2011-03-03 | 2014-07-03 | Zalicus Pharmaceuticals Ltd. | Benzimidazole inhibitors of the sodium channel |
| CA2831932A1 (en) | 2011-04-01 | 2012-10-04 | Genentech, Inc. | Combinations of akt and mek inhibitor compounds, and methods of use |
| RS56759B2 (sr) | 2011-04-01 | 2024-10-31 | Genentech Inc | Kombinacija akt inhibitor jedinjenja i abiraterona za upotrebu pri terapeutskim tretiranjima |
| WO2012163792A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| WO2012163456A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| ES2574840T3 (es) | 2011-07-22 | 2016-06-22 | Actelion Pharmaceuticals Ltd. | Derivados de amidas heterocíclicas como antagonistas de receptores p2x7 |
| KR102033190B1 (ko) | 2012-01-20 | 2019-10-16 | 이도르시아 파마슈티컬스 리미티드 | Ｐ２ｘ７ 수용체 길항제로서의 헤테로시클릭 아미드 유도체 |
| US9075975B2 (en) * | 2012-02-21 | 2015-07-07 | Andrew Bud | Online pseudonym verification and identity validation |
| EA029644B1 (ru) | 2012-12-12 | 2018-04-30 | Идорсиа Фармасьютиклз Лтд | Индолкарбоксамидные производные в качестве антагонистов p2xрецепторов |
| CA2891499C (en) | 2012-12-18 | 2021-07-06 | Actelion Pharmaceuticals Ltd | Indole carboxamide derivatives as p2x7 receptor antagonists |
| CA2896790C (en) | 2013-01-22 | 2022-05-10 | Actelion Pharmaceuticals Ltd | Heterocyclic amide derivatives as p2x7 receptor antagonists |
| KR102220847B1 (ko) | 2013-01-22 | 2021-02-26 | 이도르시아 파마슈티컬스 리미티드 | Ｐ2ｘ7 수용체 길항제로서의 헤테로시클릭 아미드 유도체 |
| TWI636047B (zh) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | 雜環衍生物 |
| FR3026102A1 (fr) * | 2014-09-19 | 2016-03-25 | Univ Nice Sophia Antipolis | Conjugues d'acide amine-pyridine/pyridinium et leurs utilisations en tant qu'agents biocides |
| GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| JP6884801B2 (ja) | 2016-05-31 | 2021-06-09 | カルビスタ・ファーマシューティカルズ・リミテッド | 血漿カリクレインインヒビターとしてのピラゾール誘導体 |
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| DE102016111711A1 (de) * | 2016-06-27 | 2017-12-28 | Abb Schweiz Ag | Installationsschaltgerät mit einem Gehäuse und mit einer Schraubanschlussklemme |
| DK3609868T3 (da) * | 2017-03-13 | 2023-11-27 | Raqualia Pharma Inc | Tetrahydroquinolinderivater som P2X7-receptorantagonister |
| WO2019006074A1 (en) * | 2017-06-28 | 2019-01-03 | Indiana University Research And Technology Corporation | PHARMACEUTICAL AGENT THAT RELATES TO THE P2X7 RECEIVER |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| MX2020005168A (es) | 2017-11-29 | 2020-08-20 | Kalvista Pharmaceuticals Ltd | Formas de dosificacion que contienen un inhibidor calicreina de plasma. |
| WO2019185868A1 (en) * | 2018-03-29 | 2019-10-03 | Centre National De La Recherche Scientifique | P2rx7 modulators in therapy |
| EP4010333A1 (en) | 2019-08-09 | 2022-06-15 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
| JP2023521623A (ja) | 2020-03-31 | 2023-05-25 | ノモレイティス・ベスローテン・フェンノートシャップ | 過炎症性症候群の処置 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2651639A (en) * | 1951-08-22 | 1953-09-08 | American Cyanamid Co | 2-pyrrolidone-5-carboxamide derivatives and methods of preparing the same |
| FR2273533A1 (fr) * | 1974-06-04 | 1976-01-02 | Ferlux Sa | Nouveaux derives n-substitues d'acides pyrrolidones-2 carboxyliques-5 |
| JPH0699307B2 (ja) * | 1987-08-20 | 1994-12-07 | キッセイ薬品工業株式会社 | 抗痴呆剤 |
| US4772601A (en) * | 1988-01-25 | 1988-09-20 | Hoechst-Roussel Pharmaceuticals, Inc. | 5-Substituted 1-(4-(1-pyrrolidinyl)-2-butynyl)-2-pyrrolidinones, pharmaceutical compositions and use |
| US6191146B1 (en) | 1995-11-13 | 2001-02-20 | Smithkline Beecham Corporation | Hemoregulatory compounds |
| US6054579A (en) * | 1997-06-26 | 2000-04-25 | Leukosite, Inc. | Synthesis of substituted lactams |
| SE9704546D0 (sv) * | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| SE9704544D0 (sv) * | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| AU2160900A (en) | 1998-12-11 | 2000-06-26 | American Biogenetic Sciences, Inc. | Substituted nitrogen heterocyclic compounds and therapeutic uses thereof |
| CN1215028C (zh) | 2002-05-24 | 2005-08-17 | 中国科学院上海有机化学研究所 | 外消旋的联二酚的光学拆分方法 |
| US7288538B2 (en) * | 2003-02-20 | 2007-10-30 | Encysive Pharmaceuticals, Inc. | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists |
| DE602004018338D1 (de) * | 2003-09-22 | 2009-01-22 | Onepharm Res And Dev Gmbh | Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund |
| US20080021034A1 (en) * | 2006-04-10 | 2008-01-24 | Painceptor Pharma Corporation | Compositions and methods for modulating gated ion channels |
| WO2008005368A2 (en) * | 2006-06-30 | 2008-01-10 | Abbott Laboratories | Piperazines as p2x7 antagonists |
| PL2049478T3 (pl) | 2006-07-06 | 2012-09-28 | Glaxo Group Ltd | Podstawione N-fenylometylo 5-okso-prolino-2-amidy jako antagoniści receptora P2X7 oraz sposoby ich zastosowania |
| MX2009000801A (es) * | 2006-07-22 | 2009-02-03 | Oxagen Ltd | Compuestos que tienen actividad antagonista crth2. |
| CN101621931A (zh) * | 2006-11-27 | 2010-01-06 | H.隆德贝克有限公司 | 杂芳基酰胺衍生物 |
| CN101686680B (zh) * | 2007-03-09 | 2015-12-09 | 伊沃泰克美国股份有限公司 | 作为p2x7调节剂的双环杂芳基化合物及其用途 |
| GB0705882D0 (en) * | 2007-03-27 | 2007-05-02 | Glaxo Group Ltd | Novel compounds |
| JP2010522711A (ja) * | 2007-03-28 | 2010-07-08 | グラクソ グループ リミテッド | Ｐ２ｘ７調節因子としてのピペリジノンカルボキサミド誘導体 |
| JP2010522710A (ja) * | 2007-03-29 | 2010-07-08 | グラクソ グループ リミテッド | Ｐ２ｘ７調節因子としてのオキサゾリジンおよびモルホリンカルボキサミド誘導体 |
| WO2008119825A2 (en) * | 2007-04-03 | 2008-10-09 | Glaxo Group Limited | Imidazolidine carboxamide derivatives as p2x7 modulators |
| CN101772498A (zh) * | 2007-04-10 | 2010-07-07 | H.隆德贝克有限公司 | 作为p2x7拮抗剂的杂芳基酰胺类似物 |
-
2007
- 2007-07-03 PL PL07787001T patent/PL2049478T3/pl unknown
- 2007-07-03 KR KR1020097002352A patent/KR101398264B1/ko not_active Expired - Fee Related
- 2007-07-03 BR BRPI0714062-2A patent/BRPI0714062A2/pt not_active IP Right Cessation
- 2007-07-03 SI SI200730962T patent/SI2049478T1/sl unknown
- 2007-07-03 US US11/772,977 patent/US7718693B2/en not_active Expired - Fee Related
- 2007-07-03 CA CA002655675A patent/CA2655675A1/en not_active Abandoned
- 2007-07-03 WO PCT/EP2007/056675 patent/WO2008003697A1/en not_active Ceased
- 2007-07-03 MX MX2009000117A patent/MX2009000117A/es active IP Right Grant
- 2007-07-03 HR HRP20120505TT patent/HRP20120505T1/hr unknown
- 2007-07-03 DK DK07787001.2T patent/DK2049478T3/da active
- 2007-07-03 KR KR1020147001116A patent/KR20140016431A/ko not_active Ceased
- 2007-07-03 EP EP07787001A patent/EP2049478B1/en active Active
- 2007-07-03 EA EA200970085A patent/EA016076B1/ru not_active IP Right Cessation
- 2007-07-03 AU AU2007271182A patent/AU2007271182B2/en not_active Ceased
- 2007-07-03 ES ES07787001T patent/ES2385505T3/es active Active
- 2007-07-03 UA UAA200900103A patent/UA100227C2/uk unknown
- 2007-07-03 JP JP2009517252A patent/JP5283620B2/ja not_active Expired - Fee Related
- 2007-07-03 PT PT07787001T patent/PT2049478E/pt unknown
- 2007-07-04 AR ARP070102985A patent/AR061815A1/es unknown
- 2007-07-04 PE PE2007000855A patent/PE20080997A1/es not_active Application Discontinuation
- 2007-07-04 TW TW096124227A patent/TW200819127A/zh unknown
-
2008
- 2008-12-19 CR CR10545A patent/CR10545A/es unknown
- 2008-12-25 IL IL196181A patent/IL196181A0/en unknown
-
2009
- 2009-01-16 NO NO20090267A patent/NO20090267L/no not_active Application Discontinuation
- 2009-01-30 MA MA31599A patent/MA30607B1/fr unknown
-
2010
- 2010-02-18 US US12/708,077 patent/US8048907B2/en not_active Expired - Fee Related
-
2012
- 2012-07-26 CY CY20121100671T patent/CY1113415T1/el unknown
-
2014
- 2014-11-10 CR CR20140515A patent/CR20140515A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR061815A1 (es) | Compuesto de oxo-prolinamida composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento | |
| AR063602A1 (es) | Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos. | |
| AR059957A1 (es) | DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER. | |
| CY1118292T1 (el) | Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων | |
| AR066583A1 (es) | Derivados de 3,3-espiroindolinona | |
| AR074426A1 (es) | Compuesto de n-(((1s,4s,6s)-3-(2-piridinilcarbonil)3-azabiciclo (4,1.0)hept-4-il) metil)-2-heteroarilamina, su uso para la prepracion de un medicamento para el tratamiento de una enfermedad que requiere un antagonista de un receptor de orexina humana y composicion farmaceutica que lo comprende | |
| CL2008002863A1 (es) | Compuestos derivados de 1,1,1-trifluoro-2-hidroxi-3-fenilpropano sustituidos; el procedimiento de preparacion de los compuestos; su composicion farmaceutica; y uso en el tratamiento de la diabetes y enfermedades mediadas por glucocorticoides. | |
| CL2008001946A1 (es) | Compuestos derivados de imidazol, antagonistas de receptores ccr2, ccr3, ccr5; procedimiento de preparacion; y uso en el tratamiento de enfermedades vasculares perifericas. | |
| AR076171A1 (es) | Pirazolopirimidinonas 1,6-disustituidas, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento del alzheimer, epilepsia y otras enfermedades del sistema nervioso central. | |
| ECSP055853A (es) | Nuevos derivados de fluoroglicosidos heterociclicos, productos farmaceuticos que contienen dichos compuestos, y el uso de los mismos | |
| AR065093A1 (es) | Compuestos farmacéuticos inhibidores de la biosintesis de leucotrienos | |
| AR049126A1 (es) | Derivados de 5, 6, 7, 8 - tetrahidroimidazo[1,5a]piridina con actividad inhibitoria de la aldosterona sintasa, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento del hiperaldosterismo y del sindrome de cushing. | |
| PA8783601A1 (es) | Derivados de piperidina/piperazina | |
| ECSP077185A (es) | Derivados de piridina | |
| AR073314A1 (es) | Derivados de indazol o de 4,5,6,7-tetrahidro-indazol | |
| UY29427A1 (es) | Derivados sustituidos de 2,3,4,5- tetrahidro-1h-pirido (4,3-b) indol, composiciones que los contienen, procesos de preparación y aplicaciones | |
| UY30316A1 (es) | Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones | |
| AR072809A1 (es) | Compuesto de (3- piridinilcarbonil)-4-(fenilsulfonilpiperazina ), su uso para la elaboracion de unmedicamento para el tratamiento del dolor y composicion farmaceutica que lo comprende | |
| HRP20080052T3 (hr) | Derivati tropana supstituirani imidazopiridinom santagonističkim djelovanjem na ccr5 receptor za liječenje hiv-a i upala | |
| CR9616A (es) | Composiciones inyectables novedosas y procedimiento para la preparacion de dichas composiciones | |
| CY1116190T1 (el) | Φαρμακευτικη συνθεση η οποια περιεχει οπτικα ενεργη ενωση που διαθετει δραστικοτητα αγωνιστη υποδοχεα θρομβοποιητινης και ενδιαμεσο γι' αυτην | |
| ECSP099442A (es) | Derivados de heteroaril-pirrolidinil- y -piperidinil-cetona | |
| AR072189A1 (es) | Derivados heterociclicos de benzo[b][1,4] oxazinonas moduladores de adrenoreceptores beta 2, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento de enfermedades del aparato respiratorio. | |
| AR062737A1 (es) | Composicion farmaceutica que comprende un compuesto derivado de aril-azabiciclo, compuesto correspondiente y su uso para la preparacion de un medicamento | |
| AR045155A1 (es) | Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos |